https://mindmedicinelaw.com/briefing/speech-dynamics-in-psilocybin-therapy-for-ptsd-new-insights-20260716-22979The Psychedelic Journalen2026-07-17T15:06:08.547621+00:00Speech Dynamics in Psilocybin Therapy for PTSD: New Insightspsilocybin therapy, PTSD treatment, speech dynamics, psychedelic-assisted therapy, clinical trials, Compass Pathfinder Ltd, non-directive support, introspective states, therapeutic protocolshttps://mindmedicinelaw.com/briefing/ketamine-therapy-gains-traction-in-iowa-amid-depression-treatment-challenges-20260716-22907The Psychedelic Journalen2026-07-16T22:05:30.429260+00:00Ketamine Therapy Gains Traction in Iowa Amid Depression Treatment Challengesketamine therapy, depression treatment, psychedelic-assisted therapy, mental health care, Iowa, regulation, access to treatment, long-term efficacy, psychedelic researchhttps://mindmedicinelaw.com/briefing/fda-guidance-may-reshape-psychedelic-trials-in-the-us-20260716-22904The Psychedelic Journalen2026-07-16T22:04:42.118565+00:00FDA Guidance May Reshape Psychedelic Trials in the USFDA guidance, psychedelic trials, clinical trial design, drug development, psychedelic research, psilocybin, MDMA, regulatory framework, participant safety, therapeutic potentialhttps://mindmedicinelaw.com/briefing/clia-regulations-update-implications-for-psychedelic-research-20260716-22610The Psychedelic Journalen2026-07-16T15:06:34.838936+00:00CLIA Regulations Update: Implications for Psychedelic ResearchCLIA regulations, psychedelic research, clinical trials, laboratory standards, biosafety, cybersecurity, CMS, CDC, laboratory testing, RFIhttps://mindmedicinelaw.com/briefing/medicare-2027-policies-implications-for-psychedelic-therapies-20260716-22593The Psychedelic Journalen2026-07-16T15:06:19.261266+00:00Medicare 2027 Policies: Implications for Psychedelic TherapiesMedicare 2027, psychedelic therapies, payment policies, healthcare landscape, reimbursement, emerging treatments, clinical evidence, regulatory approval, healthcare policy, stakeholder advocacyhttps://mindmedicinelaw.com/briefing/white-matter-signals-new-insights-in-brain-monitoring-20260715-23003The Psychedelic Journalen2026-07-17T15:06:24.733017+00:00White Matter Signals: New Insights in Brain Monitoringwhite matter signals, electrophysiological features, brain monitoring, drug-resistant epilepsy, stereo-electroencephalography, signal complexity, fractional anisotropy, cognitive control taskhttps://mindmedicinelaw.com/briefing/psychotropic-drug-monitoring-in-bariatric-surgery-patients-20260715-23014The Psychedelic Journalen2026-07-17T15:06:17.291792+00:00Psychotropic Drug Monitoring in Bariatric Surgery Patientspsychotropic drugs, bariatric surgery, therapeutic drug monitoring, psychiatric decompensation, drug exposure changes, pharmacokinetics, lithium, tricyclic antidepressants, clozapine, clinical trialshttps://mindmedicinelaw.com/briefing/ctbs-reduces-relapse-in-alcohol-use-disorder-clinical-trial-insights-20260715-22959The Psychedelic Journalen2026-07-17T15:05:47.120247+00:00cTBS Reduces Relapse in Alcohol Use Disorder: Clinical Trial Insightscontinuous theta-burst stimulation, alcohol use disorder, neuromodulation, relapse prevention, neural networks, gene expression, clinical trial, neuroplasticity, brain stimulation, addiction treatmenthttps://mindmedicinelaw.com/briefing/psilocybin-and-synaptic-plasticity-contextual-effects-in-therapy-20260715-22961The Psychedelic Journalen2026-07-17T15:05:35.848985+00:00Psilocybin and Synaptic Plasticity: Contextual Effects in Therapypsilocybin, synaptic plasticity, psychedelic therapy, environmental context, neuroplasticity, clinical trials, brain plasticity, therapeutic setting, psychedelic research, mental healthhttps://mindmedicinelaw.com/briefing/sex-dependent-effects-of-psychedelics-insights-from-rodent-models-20260715-22786The Psychedelic Journalen2026-07-16T22:05:21.058322+00:00Sex-Dependent Effects of Psychedelics: Insights from Rodent Modelssex-dependent effects, psychedelics, rodent models, 5-HT2A receptor, neuroplasticity, clinical applications, personalized therapies, pharmacodynamics, serotonergic signaling, disease modelshttps://mindmedicinelaw.com/briefing/psilocybin-s-dual-role-therapy-and-spirituality-explored-20260714-22463The Psychedelic Journalen2026-07-16T15:07:13.450623+00:00Psilocybin's Dual Role: Therapy and Spirituality Exploredpsilocybin, therapeutic potential, spiritual practices, neuroplasticity, shamanic traditions, psychedelic-assisted therapy, mental health, clinical psychiatry, cultural integration, ethical considerationshttps://mindmedicinelaw.com/briefing/psilocybin-s-therapeutic-and-spiritual-potential-a-scholarly-analysis-20260714-22462The Psychedelic Journalen2026-07-16T15:07:06.045797+00:00Psilocybin's Therapeutic and Spiritual Potential: A Scholarly Analysispsilocybin research, therapeutic potential, spiritual practices, neuroplasticity, mental health, psychedelic renaissance, psychopharmacology, ancient traditions, psychiatric care, clinical protocolshttps://mindmedicinelaw.com/briefing/ketamine-therapy-at-imh-a-new-hope-for-depression-in-singapore-20260714-22405The Psychedelic Journalen2026-07-16T15:06:58.125065+00:00Ketamine Therapy at IMH: A New Hope for Depression in Singaporeketamine therapy, treatment-resistant depression, Institute of Mental Health, psychedelic therapies, mental health care, Singapore mental healthhttps://mindmedicinelaw.com/briefing/eeg-based-ml-predicts-anxiety-in-adolescents-with-mdd-20260714-22623The Psychedelic Journalen2026-07-16T15:06:44.899986+00:00EEG-Based ML Predicts Anxiety in Adolescents with MDDEEG, machine learning, adolescent mental health, major depressive disorder, comorbid anxiety, personalized diagnostics, translational psychiatry, biomarker-based diagnosticshttps://mindmedicinelaw.com/briefing/psilocybin-s-therapeutic-and-spiritual-potential-shurooms-analysis-20260714-22460The Psychedelic Journalen2026-07-15T22:05:47.068895+00:00Psilocybin's Therapeutic and Spiritual Potential: Shurooms Analysispsilocybin, psychedelic therapy, neuroplasticity, mental health, spiritual practices, entheogens, Ajarn Shaman Shu, treatment-resistant depression, anxiety, PTSDhttps://mindmedicinelaw.com/briefing/psilocybin-in-palliative-care-promising-pilot-study-results-20260714-22461The Psychedelic Journalen2026-07-15T22:05:02.508093+00:00Psilocybin in Palliative Care: Promising Pilot Study Resultspsilocybin-assisted therapy, palliative care, demoralization, chronic pain, cancer patients, psychedelic research, clinical trials, mental health, spiritual health, multidisciplinary carehttps://mindmedicinelaw.com/briefing/federal-agencies-back-psychedelics-fda-and-hrsa-lead-20260713-22905The Psychedelic Journalen2026-07-16T22:05:11.638631+00:00Federal Agencies Back Psychedelics: FDA and HRSA LeadFDA, HRSA, psychedelic research, breakthrough therapy, mental health, psilocybin, MDMA, clinical trials, federal policy, market opportunitieshttps://mindmedicinelaw.com/briefing/fda-finalizes-psychedelic-research-guidance-sets-hearing-20260713-22906The Psychedelic Journalen2026-07-16T22:05:00.673376+00:00FDA Finalizes Psychedelic Research Guidance, Sets HearingFDA guidance, psychedelic research, therapeutic uses, clinical trials, mental health, policy implications, safety monitoring, psilocybin, MDMA, regulatory frameworkhttps://mindmedicinelaw.com/briefing/va-hhs-launch-psychedelic-therapy-for-veterans-20260713-22909The Psychedelic Journalen2026-07-16T22:04:51.753736+00:00VA & HHS Launch Psychedelic Therapy for Veteranspsychedelic therapies, veteran mental health, VA and HHS partnership, psilocybin, MDMA, federal policy, PTSD treatment, mental health innovation, Schedule I substances, clinical trialshttps://mindmedicinelaw.com/briefing/systems-based-psychiatry-insights-from-psychedelic-research-20260713-22465The Psychedelic Journalen2026-07-15T22:05:30.304495+00:00Systems-Based Psychiatry: Insights from Psychedelic Researchpsychedelic research, systems-based psychiatry, psychiatric disorders, therapeutic reorganization, mental health care, clinical implementationhttps://mindmedicinelaw.com/briefing/psilocybin-therapy-trials-reporting-practices-and-gaps-20260713-22466The Psychedelic Journalen2026-07-15T22:05:23.605307+00:00Psilocybin Therapy Trials: Reporting Practices and Gapspsilocybin-assisted therapy, depression trials, reporting practices, clinical trial standardization, blinding success, therapist fidelity, psychedelic research, treatment-resistant depression, neuroscience, public healthhttps://mindmedicinelaw.com/briefing/sex-differences-in-psychedelic-responses-implications-for-trials-20260713-22464The Psychedelic Journalen2026-07-15T22:05:12.403433+00:00Sex Differences in Psychedelic Responses: Implications for Trialspsychedelic research, sex differences, clinical trials, subjective effects, dosing strategies, safety protocols, pharmacodynamicshttps://mindmedicinelaw.com/briefing/epigenetic-effects-of-psychedelics-and-ketamine-implications-for-therapy-20260710-23047The Psychedelic Journalen2026-07-17T15:05:58.071097+00:00Epigenetic Effects of Psychedelics and Ketamine: Implications for Therapyepigenetic changes, psychedelics, ketamine, mental health treatment, neuromodulation, clinical trials, DNA methylation, histone modification, therapeutic strategies, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/dmt-s-proliferative-effects-on-neural-stem-cells-implications-20260709-22395The Psychedelic Journalen2026-07-15T22:05:38.169440+00:00DMT's Proliferative Effects on Neural Stem Cells: ImplicationsDMT, neural stem cells, neurogenesis, psychedelic research, neurodegenerative diseases, serotonin receptors, clinical trials, Schedule I substance, brain plasticity, therapeutic applications